Skip to main content
Erschienen in: Inflammation 4/2023

10.04.2023 | RESEARCH

Deletion of DYRK1A Accelerates Osteoarthritis Progression Through Suppression of EGFR-ERK Signaling

verfasst von: Zhibo Liu, Shidong Hu, Jiangping Wu, Xiaolin Quan, Chen Shen, Zhi Li, Xin Yuan, Xiangwei Li, Chao Yu, Ting Wang, Xudong Yao, Xianding Sun, Mao Nie

Erschienen in: Inflammation | Ausgabe 4/2023

Einloggen, um Zugang zu erhalten

Abstract

Dual-specificity tyrosine phosphorylation regulated kinase 1A (DYRK1A) signaling is involved in the dynamic balance of catabolism and anabolism in articular chondrocytes. This study aimed to investigate the roles and mechanism of DYRK1A in the pathogenesis of osteoarthritis (OA). The expressions of DYRK1A and its downstream signal epidermal growth factor receptor (EGFR) were detected in the cartilage of adult wild-type mice with destabilized medial meniscus (DMM) and articular cartilage of patients with OA. We measured the progression of osteoarthritis in chondrocyte-specific knockout DYRK1A(DYRK1A-cKO) mice after DMM surgery. Knee cartilage was histologically scored and assessed the effects of DYRK1A deletion on chondrocyte catabolism and anabolism. The effect of inhibiting EGFR signaling in chondrocytes from DYRK1A-cKO mice was analyzed. Trauma-induced OA mice and OA patients showed downregulation of DYRK1A and EGFR signaling pathways. Conditional DYRK1A deletion aggravates DMM-induced cartilage degeneration, reduces the thickness of the superficial cartilage, and increases the number of hypertrophic chondrocytes. The expression of collagen type II, p-ERK, and aggrecan was also downregulated, and the expression of collagen type X was upregulated in the articular cartilage of these mice. Our findings suggest that DYRK1A delays the progression of knee osteoarthritis in mice, at least in part, by maintaining EGFR-ERK signaling in articular chondrocytes.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Glyn-Jones, S., A.J. Palmer, R. Agricola, A.J. Price, T.L. Vincent, H. Weinans, et al. 2015. Osteoarthritis. Lancet 386 (9991): 376–87. [eng]. Glyn-Jones, S., A.J. Palmer, R. Agricola, A.J. Price, T.L. Vincent, H. Weinans, et al. 2015. Osteoarthritis. Lancet 386 (9991): 376–87. [eng].
2.
Zurück zum Zitat Bijlsma, J.W., F. Berenbaum, and F.P. Lafeber. 2011. Osteoarthritis: An update with relevance for clinical practice. Lancet 377 (9783): 2115–26. [eng]. Bijlsma, J.W., F. Berenbaum, and F.P. Lafeber. 2011. Osteoarthritis: An update with relevance for clinical practice. Lancet 377 (9783): 2115–26. [eng].
3.
Zurück zum Zitat Pest, M.A., B.A. Russell, Y.W. Zhang, J.W. Jeong, and F. Beier. 2014. Disturbed cartilage and joint homeostasis resulting from a loss of mitogen-inducible gene 6 in a mouse model of joint dysfunction. Arthritis Rheumatol 66 (10): 2816–27. [eng]. Pest, M.A., B.A. Russell, Y.W. Zhang, J.W. Jeong, and F. Beier. 2014. Disturbed cartilage and joint homeostasis resulting from a loss of mitogen-inducible gene 6 in a mouse model of joint dysfunction. Arthritis Rheumatol 66 (10): 2816–27. [eng].
4.
Zurück zum Zitat Sun, H., Y. Wu, Z. Pan, D. Yu, P. Chen, X. Zhang, et al. 2018. Gefitinib for epidermal growth factor receptor activated osteoarthritis subpopulation Tteatment. EBioMedicine 32: 223–33. [eng]. Sun, H., Y. Wu, Z. Pan, D. Yu, P. Chen, X. Zhang, et al. 2018. Gefitinib for epidermal growth factor receptor activated osteoarthritis subpopulation Tteatment. EBioMedicine 32: 223–33. [eng].
5.
Zurück zum Zitat Jia, H., X. Ma, W. Tong, B. Doyran, Z. Sun, L. Wang, et al. 2016. EGFR signaling is critical for maintaining the superficial layer of articular cartilage and preventing osteoarthritis initiation. Proceedings of the National Academy of Sciences USA 113 (50): 14360–65. [eng]. Jia, H., X. Ma, W. Tong, B. Doyran, Z. Sun, L. Wang, et al. 2016. EGFR signaling is critical for maintaining the superficial layer of articular cartilage and preventing osteoarthritis initiation. Proceedings of the National Academy of Sciences USA 113 (50): 14360–65. [eng].
6.
Zurück zum Zitat Wei, Y., L. Luo, T. Gui, F. Yu, L. Yan, L. Yao, et al. 2021. Targeting cartilage EGFR pathway for osteoarthritis treatment. Science Translational Medicine 13 (576). [eng]. Wei, Y., L. Luo, T. Gui, F. Yu, L. Yan, L. Yao, et al. 2021. Targeting cartilage EGFR pathway for osteoarthritis treatment. Science Translational Medicine 13 (576). [eng].
7.
Zurück zum Zitat Pozo, N., C. Zahonero, P. Fernández, J.M. Liñares, A. Ayuso, M. Hagiwara M, et al. 2013. Inhibition of DYRK1A destabilizes EGFR and reduces EGFR-dependent glioblastoma growth. Journal of Clinical Investigation 123 (6): 2475–87. [eng]. Pozo, N., C. Zahonero, P. Fernández, J.M. Liñares, A. Ayuso, M. Hagiwara M, et al. 2013. Inhibition of DYRK1A destabilizes EGFR and reduces EGFR-dependent glioblastoma growth. Journal of Clinical Investigation 123 (6): 2475–87. [eng].
8.
Zurück zum Zitat Arbones, M.L., A. Thomazeau, A. Nakano-Kobayashi, M. Hagiwara, and J.M. Delabar. 2019. DYRK1A and cognition: A lifelong relationship. Pharmacology and Therapeutics 194: 199–221. [eng]. Arbones, M.L., A. Thomazeau, A. Nakano-Kobayashi, M. Hagiwara, and J.M. Delabar. 2019. DYRK1A and cognition: A lifelong relationship. Pharmacology and Therapeutics 194: 199–221. [eng].
9.
Zurück zum Zitat Luna, J., J. Boni, M. Cuatrecasas, X. Bofill-De Ros, E. Núñez-Manchón, M. Gironella M, et al. 2019. DYRK1A modulates c-MET in pancreatic ductal adenocarcinoma to drive tumour growth. Gut 68(8):1465–76. [eng]. Luna, J., J. Boni, M. Cuatrecasas, X. Bofill-De Ros, E. Núñez-Manchón, M. Gironella M, et al. 2019. DYRK1A modulates c-MET in pancreatic ductal adenocarcinoma to drive tumour growth. Gut 68(8):1465–76. [eng].
10.
Zurück zum Zitat Deshmukh, V., A.L. O’Green, C. Bossard, T. Seo, L. Lamangan, M. Ibanez, et al. 2019. Modulation of the Wnt pathway through inhibition of CLK2 and DYRK1A by lorecivivint as a novel, potentially disease-modifying approach for knee osteoarthritis treatment. Osteoarthritis Cartilage 27 (9): 1347–60. [eng]. Deshmukh, V., A.L. O’Green, C. Bossard, T. Seo, L. Lamangan, M. Ibanez, et al. 2019. Modulation of the Wnt pathway through inhibition of CLK2 and DYRK1A by lorecivivint as a novel, potentially disease-modifying approach for knee osteoarthritis treatment. Osteoarthritis Cartilage 27 (9): 1347–60. [eng].
11.
Zurück zum Zitat Forristal, C., S.A. Henley, J.I. MacDonald, J.R. Bush, C. Ort, D.T. Passos, et al. 2014. Loss of the mammalian DREAM complex deregulates chondrocyte proliferation. Molecular and Cellular Biology 34 (12): 2221–34. [eng]. Forristal, C., S.A. Henley, J.I. MacDonald, J.R. Bush, C. Ort, D.T. Passos, et al. 2014. Loss of the mammalian DREAM complex deregulates chondrocyte proliferation. Molecular and Cellular Biology 34 (12): 2221–34. [eng].
12.
Zurück zum Zitat Guo, G., K. Gong, S. Ali, N. Ali, S. Shallwani, K.J. Hatanpaa, et al. 2017. A TNF-JNK-Axl-ERK signaling axis mediates primary resistance to EGFR inhibition in glioblastoma. Nature Neuroscience 20 (8): 1074–84. [eng]. Guo, G., K. Gong, S. Ali, N. Ali, S. Shallwani, K.J. Hatanpaa, et al. 2017. A TNF-JNK-Axl-ERK signaling axis mediates primary resistance to EGFR inhibition in glioblastoma. Nature Neuroscience 20 (8): 1074–84. [eng].
13.
Zurück zum Zitat Glasson, S.S., T.J. Blanchet, and E.A Morris. 2007. The surgical destabilization of the medial meniscus (DMM) model of osteoarthritis in the 129/SvEv mouse. Osteoarthritis Cartilage 15 (9): 1061–9. [eng]. Glasson, S.S., T.J. Blanchet, and E.A Morris. 2007. The surgical destabilization of the medial meniscus (DMM) model of osteoarthritis in the 129/SvEv mouse. Osteoarthritis Cartilage 15 (9): 1061–9. [eng].
14.
Zurück zum Zitat Ricciotti, E., C. Castro, S.Y. Tang, W.T.E. Briggs, J.A. West, D. Malik, et al. 2018. Cyclooxygenase-2, asymmetric dimethylarginine, and the cardiovascular hazard from nonsteroidal anti-inflammatory drugs. Circulation 138 (21): 2367–78. [eng]. Ricciotti, E., C. Castro, S.Y. Tang, W.T.E. Briggs, J.A. West, D. Malik, et al. 2018. Cyclooxygenase-2, asymmetric dimethylarginine, and the cardiovascular hazard from nonsteroidal anti-inflammatory drugs. Circulation 138 (21): 2367–78. [eng].
15.
Zurück zum Zitat Roelofs, A.J., K. Kania, A.J. Rafipay, M. Sambale, S.T. Kuwahara, F.L. Collins, et al. 2020. Identification of the skeletal progenitor cells forming osteophytes in osteoarthritis. Annals of Rheumatic Diseases 79 (12): 1625–34. [eng]. Roelofs, A.J., K. Kania, A.J. Rafipay, M. Sambale, S.T. Kuwahara, F.L. Collins, et al. 2020. Identification of the skeletal progenitor cells forming osteophytes in osteoarthritis. Annals of Rheumatic Diseases 79 (12): 1625–34. [eng].
16.
Zurück zum Zitat Kuang, L., J. Wu, N. Su, H. Qi, H. Chen, S. Zhou, et al. 2020. FGFR3 deficiency enhances CXCL12-dependent chemotaxis of macrophages via upregulating CXCR7 and aggravates joint destruction in mice. Annals of Rheumatic Diseases 79 (1): 112–22. [eng]. Kuang, L., J. Wu, N. Su, H. Qi, H. Chen, S. Zhou, et al. 2020. FGFR3 deficiency enhances CXCL12-dependent chemotaxis of macrophages via upregulating CXCR7 and aggravates joint destruction in mice. Annals of Rheumatic Diseases 79 (1): 112–22. [eng].
17.
Zurück zum Zitat Chen, X., W. Gong, X. Shao, T. Shi, L. Zhang, J. Dong, et al. 2022. METTL3-mediated m(6)A modification of ATG7 regulates autophagy-GATA4 axis to promote cellular senescence and osteoarthritis progression. Annals of Rheumatic Diseases 81 (1): 87–99. [eng]. Chen, X., W. Gong, X. Shao, T. Shi, L. Zhang, J. Dong, et al. 2022. METTL3-mediated m(6)A modification of ATG7 regulates autophagy-GATA4 axis to promote cellular senescence and osteoarthritis progression. Annals of Rheumatic Diseases 81 (1): 87–99. [eng].
18.
Zurück zum Zitat Glasson, S.S., M.G. Chambers, W.B. Van Den Berg, and C.B Little. 2010. The OARSI histopathology initiative — Recommendations for histological assessments of osteoarthritis in the mouse. Osteoarthritis Cartilage 18 Suppl 3: S17–23. [eng]. Glasson, S.S., M.G. Chambers, W.B. Van Den Berg, and C.B Little. 2010. The OARSI histopathology initiative — Recommendations for histological assessments of osteoarthritis in the mouse. Osteoarthritis Cartilage 18 Suppl 3: S17–23. [eng].
19.
Zurück zum Zitat Lin, A.C., B.L. Seeto, J.M. Bartoszko, M.A. Khoury, H. Whetstone, L. Ho, et al. 2009. Modulating hedgehog signaling can attenuate the severity of osteoarthritis. Nature Medicine 15 (12): 1421–5. [eng]. Lin, A.C., B.L. Seeto, J.M. Bartoszko, M.A. Khoury, H. Whetstone, L. Ho, et al. 2009. Modulating hedgehog signaling can attenuate the severity of osteoarthritis. Nature Medicine 15 (12): 1421–5. [eng].
20.
Zurück zum Zitat Ahmed, M.I., and T.W. Lennard. 2009. Breast cancer: role of neoadjuvant therapy. International Journal of Surgery 7 (5): 416–20. [eng]. Ahmed, M.I., and T.W. Lennard. 2009. Breast cancer: role of neoadjuvant therapy. International Journal of Surgery 7 (5): 416–20. [eng].
21.
Zurück zum Zitat Hasegawa, A., T. Yonezawa, N. Taniguchi, K. Otabe, Y. Akasaki, T. Matsukawa, et al. 2017. Role of fibulin 3 in aging-related joint changes and osteoarthritis pathogenesis in human and mouse knee cartilage. Arthritis Rheumatology 69 (3): 576–85. [eng]. Hasegawa, A., T. Yonezawa, N. Taniguchi, K. Otabe, Y. Akasaki, T. Matsukawa, et al. 2017. Role of fibulin 3 in aging-related joint changes and osteoarthritis pathogenesis in human and mouse knee cartilage. Arthritis Rheumatology 69 (3): 576–85. [eng].
22.
Zurück zum Zitat Xu, X., Q. Liu, C. Zhang, S. Ren, L. Xu, Z. Zhao, et al. 2019. Inhibition of DYRK1A-EGFR axis by p53-MDM2 cascade mediates the induction of cellular senescence. Cell Death & Disease 10 (4): 282. [eng]. Xu, X., Q. Liu, C. Zhang, S. Ren, L. Xu, Z. Zhao, et al. 2019. Inhibition of DYRK1A-EGFR axis by p53-MDM2 cascade mediates the induction of cellular senescence. Cell Death & Disease 10 (4): 282. [eng].
23.
Zurück zum Zitat Smeriglio, P., J. Lee, and N. Bhutani. 2017. Soluble Collagen VI treatment enhances mesenchymal stem cells expansion for engineering cartilage. Bioengineering & Translational Medicine 2 (3): 278–84. [eng]. Smeriglio, P., J. Lee, and N. Bhutani. 2017. Soluble Collagen VI treatment enhances mesenchymal stem cells expansion for engineering cartilage. Bioengineering & Translational Medicine 2 (3): 278–84. [eng].
24.
Zurück zum Zitat Tang, J., N. Su, S. Zhou, Y. Xie, J. Huang, X. Wen, et al. 2016. Fibroblast growth factor receptor 3 inhibits osteoarthritis progression in the knee joints of adult mice. Arthritis Rheumatology 68 (10): 2432–43. [eng]. Tang, J., N. Su, S. Zhou, Y. Xie, J. Huang, X. Wen, et al. 2016. Fibroblast growth factor receptor 3 inhibits osteoarthritis progression in the knee joints of adult mice. Arthritis Rheumatology 68 (10): 2432–43. [eng].
25.
Zurück zum Zitat Zhao, Y.P., B. Liu, Q.Y. Tian, J.L. Wei, B. Richbourgh, and C.J. Liu. 2015. Progranulin protects against osteoarthritis through interacting with TNF-α and β-Catenin signalling. Annals of Rheumatic Diseases 74 (12): 2244–53. [eng]. Zhao, Y.P., B. Liu, Q.Y. Tian, J.L. Wei, B. Richbourgh, and C.J. Liu. 2015. Progranulin protects against osteoarthritis through interacting with TNF-α and β-Catenin signalling. Annals of Rheumatic Diseases 74 (12): 2244–53. [eng].
26.
Zurück zum Zitat Rubin, C., V. Litvak, H. Medvedovsky, Y. Zwang, S. Lev, and Y. Yarden. 2003. Sprouty fine-tunes EGF signaling through interlinked positive and negative feedback loops. Current Biology 13 (4): 297–307. [eng]. Rubin, C., V. Litvak, H. Medvedovsky, Y. Zwang, S. Lev, and Y. Yarden. 2003.  Sprouty fine-tunes EGF signaling through interlinked positive and negative feedback loops. Current Biology 13 (4): 297–307. [eng].
27.
Zurück zum Zitat Barnett, R. 2018. Osteoarthritis. Lancet 391 (10134): 1985. [eng]. Barnett, R. 2018. Osteoarthritis. Lancet 391 (10134): 1985. [eng].
28.
Zurück zum Zitat Katz, J.N., K.R. Arant, and R.F. Loeser. 2021. Diagnosis and treatment of hip and knee osteoarthritis: A review. Jama 325 (6): 568–78. [eng]. Katz, J.N., K.R. Arant, and R.F. Loeser. 2021. Diagnosis and treatment of hip and knee osteoarthritis: A review. Jama 325 (6): 568–78. [eng].
29.
Zurück zum Zitat Abbassi, R., T.G. Johns, M. Kassiou, and L. Munoz. 2015. DYRK1A in neurodegeneration and cancer: Molecular basis and clinical implications. Pharmacology & Therapeutics 151: 87–98. [eng]. Abbassi, R., T.G. Johns, M. Kassiou, and L. Munoz. 2015. DYRK1A in neurodegeneration and cancer: Molecular basis and clinical implications. Pharmacology & Therapeutics 151: 87–98. [eng].
30.
Zurück zum Zitat Smith, I., and F. Calegari. 2015. Cyclin D1 again caught in the act: Dyrk1a Links G1 and neurogenesis in Down syndrome. EBioMedicine 2 (2): 96–7. [eng]. Smith, I., and F. Calegari. 2015. Cyclin D1 again caught in the act: Dyrk1a Links G1 and neurogenesis in Down syndrome. EBioMedicine 2 (2): 96–7. [eng].
31.
Zurück zum Zitat Yazici, Y., T.E. McAlindon, A. Gibofsky, N.E. Lane, D. Clauw, M. Jones, et al. 2020. Lorecivivint, a novel intraarticular CDC-like kinase 2 and dual-specificity tyrosine phosphorylation-regulated kinase 1A inhibitor and Wnt pathway modulator for the treatment of knee osteoarthritis: A phase II randomized trial. Arthritis Rheumatology 2020;72(10):1694–706. [eng]. Yazici, Y., T.E. McAlindon, A. Gibofsky, N.E. Lane, D. Clauw, M. Jones, et al. 2020. Lorecivivint, a novel intraarticular CDC-like kinase 2 and dual-specificity tyrosine phosphorylation-regulated kinase 1A inhibitor and Wnt pathway modulator for the treatment of knee osteoarthritis: A phase II randomized trial. Arthritis Rheumatology 2020;72(10):1694–706. [eng].
32.
Zurück zum Zitat Trucco, D., L. Vannozzi, E. Teblum, M. Telkhozhayeva, G.D. Nessim, S. Affatato, et al. 2021. Graphene oxide-doped gellan gum-PEGDA bilayered hydrogel mimicking the mechanical and lubrication properties of articular cartilage. Advanced Healthcare Materials 10 (7): e2001434. [eng]. Trucco, D., L. Vannozzi, E. Teblum, M. Telkhozhayeva, G.D. Nessim, S. Affatato, et al. 2021. Graphene oxide-doped gellan gum-PEGDA bilayered hydrogel mimicking the mechanical and lubrication properties of articular cartilage. Advanced Healthcare Materials 10 (7): e2001434. [eng].
33.
Zurück zum Zitat Jahn, S., J. Seror, and J. Klein. 2016. Lubrication of articular cartilage. Annual Review of Biomedical Engineering 18: 235–58. [eng]. Jahn, S., J. Seror, and J. Klein. 2016. Lubrication of articular cartilage. Annual Review of Biomedical Engineering 18: 235–58. [eng].
34.
Zurück zum Zitat Qiao, Z., M. Lian, Y. Han, B. Sun, X. Zhang, W. Jiang, et al. Bioinspired stratified electrowritten fiber-reinforced hydrogel constructs with layer-specific induction capacity for functional osteochondral regeneration. Biomaterials 266:120385. [eng]. Qiao, Z., M. Lian, Y. Han, B. Sun, X. Zhang, W. Jiang, et al. Bioinspired stratified electrowritten fiber-reinforced hydrogel constructs with layer-specific induction capacity for functional osteochondral regeneration. Biomaterials 266:120385. [eng].
35.
Zurück zum Zitat Mobasheri, A., M.P. Rayman, O. Gualillo, J. Sellam, P. van der Kraan, and U. Fearon. 2017. The role of metabolism in the pathogenesis of osteoarthritis. Nature Reviews Rheumatology 13 (5): 302–11. [eng]. Mobasheri, A., M.P. Rayman, O. Gualillo, J. Sellam, P. van der Kraan, and U. Fearon. 2017. The role of metabolism in the pathogenesis of osteoarthritis. Nature Reviews Rheumatology 13 (5): 302–11. [eng].
36.
Zurück zum Zitat Pitsillides, A.A., and F. Beier. 2011. Cartilage biology in osteoarthritis—Lessons from developmental biology. Nature Reviews Rheumatology 7 (11): 654–63. [eng]. Pitsillides, A.A., and F. Beier. 2011. Cartilage biology in osteoarthritis—Lessons from developmental biology. Nature Reviews Rheumatology 7 (11): 654–63. [eng].
37.
Zurück zum Zitat Bianco, P., F.D. Cancedda, M. Riminucci, and R. Cancedda. 1998. Bone formation via cartilage models: the “borderline” chondrocyte. Matrix Biology 17 (3): 185–92. [eng]. Bianco, P., F.D. Cancedda, M. Riminucci, and R. Cancedda. 1998. Bone formation via cartilage models: the “borderline” chondrocyte. Matrix Biology 17 (3): 185–92. [eng].
38.
Zurück zum Zitat Ferron, S.R., N. Pozo, A. Laguna, S. Aranda, E. Porlan, M. Moreno, et al. 2010. Regulated segregation of kinase Dyrk1A during asymmetric neural stem cell division is critical for EGFR-mediated biased signaling. Cell Stem Cell 7 (3): 367–79. [eng]. Ferron, S.R., N. Pozo, A. Laguna, S. Aranda, E. Porlan, M. Moreno, et al. 2010. Regulated segregation of kinase Dyrk1A during asymmetric neural stem cell division is critical for EGFR-mediated biased signaling. Cell Stem Cell 7 (3): 367–79. [eng].
39.
Zurück zum Zitat Kim, H.J., L.J. Taylor, and D. Bar-Sagi. 2007. Spatial regulation of EGFR signaling by Sprouty2. Current Biology 17 (5): 455–61. [eng]. Kim, H.J., L.J. Taylor, and D. Bar-Sagi. 2007. Spatial regulation of EGFR signaling by Sprouty2. Current Biology 17 (5): 455–61. [eng].
40.
Zurück zum Zitat Han, Y., J. Wu, Z. Gong, Y. Zhou, H. Li, B. Wang, et al. 2021. Identification and development of a novel 5-gene diagnostic model based on immune infiltration analysis of osteoarthritis. Journal of Translational Medicine 19 (1): 522. [eng]. Han, Y., J. Wu, Z. Gong, Y. Zhou, H. Li, B. Wang, et al. 2021. Identification and development of a novel 5-gene diagnostic model based on immune infiltration analysis of osteoarthritis. Journal of Translational Medicine 19 (1): 522. [eng].
41.
Zurück zum Zitat Wang, G., Y. Li, G. Yang, T. Yang, L. He, and Y. Wang. 2021. Cathelicidin antimicrobial peptide (CAMP) gene promoter methylation induces chondrocyte apoptosis. Human Genomics 15 (1): 24. [eng]. Wang, G., Y. Li, G. Yang, T. Yang, L. He, and Y. Wang. 2021. Cathelicidin antimicrobial peptide (CAMP) gene promoter methylation induces chondrocyte apoptosis. Human Genomics 15 (1): 24. [eng].
42.
Zurück zum Zitat Zhang, S., K.Y.W. Teo, S.J. Chuah, R.C. Lai, S.K. Lim, and W.S. Toh. 2019. MSC exosomes alleviate temporomandibular joint osteoarthritis by attenuating inflammation and restoring matrix homeostasis. Biomaterials 200: 35–47. [eng]. Zhang, S., K.Y.W. Teo, S.J. Chuah, R.C. Lai, S.K. Lim, and W.S. Toh. 2019. MSC exosomes alleviate temporomandibular joint osteoarthritis by attenuating inflammation and restoring matrix homeostasis. Biomaterials 200: 35–47. [eng].
43.
Zurück zum Zitat Pan, Z., Y. Wu, X. Zhang, Q. Fu, J. Li, Y. Yang, et al. 2017. Delivery of epidermal growth factor receptor inhibitor via a customized collagen scaffold promotes meniscal defect regeneration in a rabbit model. Acta Biomaterialia 62: 210–21. [eng]. Pan, Z., Y. Wu, X. Zhang, Q. Fu, J. Li, Y. Yang, et al. 2017. Delivery of epidermal growth factor receptor inhibitor via a customized collagen scaffold promotes meniscal defect regeneration in a rabbit model. Acta Biomaterialia 62: 210–21. [eng].
Metadaten
Titel
Deletion of DYRK1A Accelerates Osteoarthritis Progression Through Suppression of EGFR-ERK Signaling
verfasst von
Zhibo Liu
Shidong Hu
Jiangping Wu
Xiaolin Quan
Chen Shen
Zhi Li
Xin Yuan
Xiangwei Li
Chao Yu
Ting Wang
Xudong Yao
Xianding Sun
Mao Nie
Publikationsdatum
10.04.2023
Verlag
Springer US
Erschienen in
Inflammation / Ausgabe 4/2023
Print ISSN: 0360-3997
Elektronische ISSN: 1573-2576
DOI
https://doi.org/10.1007/s10753-023-01813-6

Weitere Artikel der Ausgabe 4/2023

Inflammation 4/2023 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Herzinfarkt mit 85 – trotzdem noch intensive Lipidsenkung?

16.05.2024 Hypercholesterinämie Nachrichten

Profitieren nach einem akuten Myokardinfarkt auch Betroffene über 80 Jahre noch von einer intensiven Lipidsenkung zur Sekundärprävention? Um diese Frage zu beantworten, wurden jetzt Registerdaten aus Frankreich ausgewertet.

CKD bei Diabetes: Neuheiten und Zukunftsaussichten

16.05.2024 DDG-Jahrestagung 2024 Kongressbericht

Jeder Mensch mit Diabetes muss auf eine chronische Nierenerkrankung gescreent werden – diese neue Empfehlung spricht die KDIGO aus. Die Therapie erfolgt individuell und je nach Szenario mit verschiedenen Substanzklassen. Künftig kommt wahrscheinlich, neben RAS-Hemmung, SGLT2-Inhibition und nsMRA, eine vierte Therapiesäule hinzu.

Riesenzellarteriitis: 15% der Patienten sind von okkulter Form betroffen

16.05.2024 Riesenzellarteriitis Nachrichten

In einer retrospektiven Untersuchung haben Forschende aus Belgien und den Niederlanden die okkulte Form der Riesenzellarteriitis genauer unter die Lupe genommen. In puncto Therapie und Rezidivraten stellten sie keinen sehr großen Unterschied zu Erkrankten mit kranialen Symptomen fest.

SGLT2-Inhibitoren und GLP-1-Rezeptoragonisten im Schlagabtausch

16.05.2024 DDG-Jahrestagung 2024 Kongressbericht

Wer hat die Nase vorn – SGLT2-Inhibitoren oder GLP-1-Rezeptoragonisten? Diese Frage diskutierten zwei Experten in einer Session auf dem diesjährigen Diabetes-Kongress.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.